{"success":true,"data":{"pressRelease":{"id":"129569","rtpr_id":"nPn2906vVa","ticker":"REPL","exchange":"NASDAQ","all_tickers":["REPL"],"title":"REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact SueWallSt","author":"PR Newswire","published_at":"2026-08-27T14:07:03.228Z","article_body":"REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact SueWallSt\n\nPR Newswire\n\nNEW YORK, Aug. 27, 2026\n\nInvestors allege Replimune Group, Inc. built its RP1 regulatory strategy\naround single-arm trial designs the FDA had already questioned, including\nresponse criteria the agency said were not consistent with RECIST v1.1.\n\nNEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of\nReplimune Group, Inc. (NASDAQ: REPL) securities of a pending securities class\naction brought on behalf of investors who acquired shares between October 20,\n2025 and April 10, 2026. Find out if you might qualify for recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760312-9&h=2353481765&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Freplimune-group-inc-class-action-lawsuit-repl%3Fprid%3D200458%26wire%3D4&a=Find+out+if+you+might+qualify+for+recovery)\n. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nREPL closed at a Class Period high of $10.73 on December 8, 2025. Shares fell\n$1.15 (19.46%) to $4.76 on April 10, 2026, then $3.06 (64.29%) to $1.70 on\nApril 13, 2026, a cumulative decline of roughly $9.03 per share, or 84.16%.\nMotions for lead plaintiff must be filed with the Court by October 5, 2026.\n\nThe Alleged Clinical Trial Design Deficiency\n\nRP1 was studied in RPL-001-16 (IGNYTE) in combination with Bristol Myers\nSquibb's nivolumab. As pleaded, that trial was single-arm and was not designed\nto isolate what RP1 itself contributed to the observed response rate.\nPlaintiffs allege that this design limitation, and the FDA's previously\ncommunicated concerns about it, were not disclosed to shareholders while the\nCompany described the resubmission as a complete response to the July 2025\ncomplete response letter.\n\nRegulatory Strategy and Response Criteria\n\nThe action contends that the FDA had recommended using data from the ongoing\nPhase 3 program to potentially support accelerated approval, and had flagged\nthat the response criteria applied in RPL-001-16 were not consistent with\nRECIST v1.1 and might not be comparable to historical literature. Instead, an\nearly unplanned analysis from RP1-104 covering 40 patients, about 10% of the\nplanned 400-patient enrollment, was submitted.\n\nOperational Gaps Alleged in the RP1 Program\n\n * Trial design that allegedly could not separate RP1's effect from nivolumab's\n * Alleged failure to adopt the randomized controlled trial the agency preferred\n * Response assessment allegedly inconsistent with RECIST v1.1 standards\n * Reliance on an early unplanned interim analysis rather than planned Phase 3\ndata\n * Study design concerns the FDA stated were \"clearly communicated\" but allegedly\nunaddressed\n * Disclosure that without approval the Company might be required to restructure\nand reprioritize the RPx portfolio\n\"The complaint raises serious questions about whether shareholders received\naccurate information about the sufficiency of the RP1 trial designs that\nregulators had already scrutinized. Investors are entitled to evaluate that\nrecord for themselves.\" -- Joseph E. Levi, Esq.\n\nSubmit your information now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760312-9&h=3378205445&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Freplimune-group-inc-class-action-lawsuit-repl%3Fprid%3D200458%26wire%3D4&a=Submit+your+information+now)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the REPL Lawsuit\n\nQ: Who is eligible to join the REPL investor lawsuit? A: Investors who\npurchased REPL stock or securities between October 20, 2025 and April 10, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses -- not on whether you still hold the\nshares.\n\nQ: What court was the REPL class action filed in? A: The case was filed in\nthe United States District Court for the District of Massachusetts, governed\nby the Private Securities Litigation Reform Act of 1995.\n\nQ: Who are the defendants named in the REPL lawsuit? A: The complaint names\nReplimune Group, Inc. and individual defendants including senior executives\nwho signed SEC filings, made public statements, or certified financial\ndisclosures under Sarbanes-Oxley.\n\nQ: What do REPL investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nNo immediate action is required to remain eligible as an absent class member.\n\nQ: What documents do I need to to submit my information? A: Brokerage\nstatements or trade confirmations showing purchase dates, share quantities,\nprices paid, and any subsequent sale dates and prices.\n\nQ: What if I already sold my REPL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in the securities class action, they are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if Replimune Group, Inc. goes bankrupt before the case resolves? A:\nSecurities class action claims may survive bankruptcy in many circumstances.\nD&O insurance policies are frequently a potential source of settlement\nfunds.\n\nCONTACT:\\\n\nLevi & Korsinsky, LLP\\\n\nJoseph E. Levi, Esq.\\\n\n33 Whitehall Street, 27th Floor\\\n\nNew York, NY 10004\\\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com) \\\n\nTel: (888) SueWallSt\\\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/repl-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-replimune-group-inc-securities-lawsuit---contact-suewallst-302861285.html\n(https://www.prnewswire.com/news-releases/repl-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-replimune-group-inc-securities-lawsuit---contact-suewallst-302861285.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2913951\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2906vVa","title":"REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact SueWallSt","author":"PR Newswire","ticker":"REPL","created":"2026-08-27T14:07:03.228Z","tickers":["REPL"],"exchange":"NASDAQ","article_body":"REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact SueWallSt\n\nPR Newswire\n\nNEW YORK, Aug. 27, 2026\n\nInvestors allege Replimune Group, Inc. built its RP1 regulatory strategy\naround single-arm trial designs the FDA had already questioned, including\nresponse criteria the agency said were not consistent with RECIST v1.1.\n\nNEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of\nReplimune Group, Inc. (NASDAQ: REPL) securities of a pending securities class\naction brought on behalf of investors who acquired shares between October 20,\n2025 and April 10, 2026. Find out if you might qualify for recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760312-9&h=2353481765&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Freplimune-group-inc-class-action-lawsuit-repl%3Fprid%3D200458%26wire%3D4&a=Find+out+if+you+might+qualify+for+recovery)\n. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nREPL closed at a Class Period high of $10.73 on December 8, 2025. Shares fell\n$1.15 (19.46%) to $4.76 on April 10, 2026, then $3.06 (64.29%) to $1.70 on\nApril 13, 2026, a cumulative decline of roughly $9.03 per share, or 84.16%.\nMotions for lead plaintiff must be filed with the Court by October 5, 2026.\n\nThe Alleged Clinical Trial Design Deficiency\n\nRP1 was studied in RPL-001-16 (IGNYTE) in combination with Bristol Myers\nSquibb's nivolumab. As pleaded, that trial was single-arm and was not designed\nto isolate what RP1 itself contributed to the observed response rate.\nPlaintiffs allege that this design limitation, and the FDA's previously\ncommunicated concerns about it, were not disclosed to shareholders while the\nCompany described the resubmission as a complete response to the July 2025\ncomplete response letter.\n\nRegulatory Strategy and Response Criteria\n\nThe action contends that the FDA had recommended using data from the ongoing\nPhase 3 program to potentially support accelerated approval, and had flagged\nthat the response criteria applied in RPL-001-16 were not consistent with\nRECIST v1.1 and might not be comparable to historical literature. Instead, an\nearly unplanned analysis from RP1-104 covering 40 patients, about 10% of the\nplanned 400-patient enrollment, was submitted.\n\nOperational Gaps Alleged in the RP1 Program\n\n * Trial design that allegedly could not separate RP1's effect from nivolumab's\n * Alleged failure to adopt the randomized controlled trial the agency preferred\n * Response assessment allegedly inconsistent with RECIST v1.1 standards\n * Reliance on an early unplanned interim analysis rather than planned Phase 3\ndata\n * Study design concerns the FDA stated were \"clearly communicated\" but allegedly\nunaddressed\n * Disclosure that without approval the Company might be required to restructure\nand reprioritize the RPx portfolio\n\"The complaint raises serious questions about whether shareholders received\naccurate information about the sufficiency of the RP1 trial designs that\nregulators had already scrutinized. Investors are entitled to evaluate that\nrecord for themselves.\" -- Joseph E. Levi, Esq.\n\nSubmit your information now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760312-9&h=3378205445&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Freplimune-group-inc-class-action-lawsuit-repl%3Fprid%3D200458%26wire%3D4&a=Submit+your+information+now)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the REPL Lawsuit\n\nQ: Who is eligible to join the REPL investor lawsuit? A: Investors who\npurchased REPL stock or securities between October 20, 2025 and April 10, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses -- not on whether you still hold the\nshares.\n\nQ: What court was the REPL class action filed in? A: The case was filed in\nthe United States District Court for the District of Massachusetts, governed\nby the Private Securities Litigation Reform Act of 1995.\n\nQ: Who are the defendants named in the REPL lawsuit? A: The complaint names\nReplimune Group, Inc. and individual defendants including senior executives\nwho signed SEC filings, made public statements, or certified financial\ndisclosures under Sarbanes-Oxley.\n\nQ: What do REPL investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nNo immediate action is required to remain eligible as an absent class member.\n\nQ: What documents do I need to to submit my information? A: Brokerage\nstatements or trade confirmations showing purchase dates, share quantities,\nprices paid, and any subsequent sale dates and prices.\n\nQ: What if I already sold my REPL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in the securities class action, they are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if Replimune Group, Inc. goes bankrupt before the case resolves? A:\nSecurities class action claims may survive bankruptcy in many circumstances.\nD&O insurance policies are frequently a potential source of settlement\nfunds.\n\nCONTACT:\\\n\nLevi & Korsinsky, LLP\\\n\nJoseph E. Levi, Esq.\\\n\n33 Whitehall Street, 27th Floor\\\n\nNew York, NY 10004\\\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com) \\\n\nTel: (888) SueWallSt\\\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/repl-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-replimune-group-inc-securities-lawsuit---contact-suewallst-302861285.html\n(https://www.prnewswire.com/news-releases/repl-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-replimune-group-inc-securities-lawsuit---contact-suewallst-302861285.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2913951\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-27T14:07:03.378849977Z","server_sent_at_ms":1787839623378},"received_at":"2026-08-27T14:07:03.428Z","source_url":"https://www.prnewswire.com/news-releases/repl-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-replimune-group-inc-securities-lawsuit---contact-suewallst-302861285.html"},"analysis":{"id":"118483","press_release_id":"129569","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Levi & Korsinsky LLP reminds investors of a pending securities class action lawsuit against Replimune Group regarding securities purchased between October 20, 2025, and April 10, 2026.\n\nThe allegations claim the company built its regulatory strategy for RP1 around trial designs the FDA had previously questioned regarding response criteria.\n\nInterested investors have until October 5, 2026, to seek lead plaintiff status; contact information is provided for potential class members.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Investors are entitled to evaluate that record for themselves.","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Esq., Levi & Korsinsky LLP"}],"products":["RP1","nivolumab"],"companies":[{"name":"Replimune Group, Inc.","ticker":"REPL"},{"name":"Bristol Myers Squibb","relationship":"partner mentioned in allegations"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Levi & Korsinsky LLP (SueWallSt). No new disclosure from the issuer; no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"REPL"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky LLP reminds investors of a pending securities class action lawsuit against Replimune Group regarding securities purchased between October 20, 2025, and April 10, 2026.\n\nThe allegations claim the company built its regulatory strategy for RP1 around trial designs the FDA had previously questioned regarding response criteria.\n\nInterested investors have until October 5, 2026, to seek lead plaintiff status; contact information is provided for potential class members.","key_figures":{},"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Esq., Levi & Korsinsky LLP"}],"products":["RP1","nivolumab"],"companies":[{"name":"Replimune Group, Inc.","ticker":"REPL"},{"name":"Bristol Myers Squibb","relationship":"partner mentioned in allegations"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T16:02:25.299Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":260531,"modelName":"glm-4.7"}}